MA41159A - Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques - Google Patents

Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques

Info

Publication number
MA41159A
MA41159A MA041159A MA41159A MA41159A MA 41159 A MA41159 A MA 41159A MA 041159 A MA041159 A MA 041159A MA 41159 A MA41159 A MA 41159A MA 41159 A MA41159 A MA 41159A
Authority
MA
Morocco
Prior art keywords
octreotide
association
oral administration
therapeutic agents
therapeutic
Prior art date
Application number
MA041159A
Other languages
English (en)
Inventor
Dana Gelbaum
Asi Haviv
Roni Mamluk
Original Assignee
Chiasma Inc
Dana Gelbaum
Roni Mamluk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiasma Inc, Dana Gelbaum, Roni Mamluk filed Critical Chiasma Inc
Publication of MA41159A publication Critical patent/MA41159A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041159A 2014-12-10 2015-12-10 Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques MA41159A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090130P 2014-12-10 2014-12-10

Publications (1)

Publication Number Publication Date
MA41159A true MA41159A (fr) 2021-05-12

Family

ID=56108186

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041159A MA41159A (fr) 2014-12-10 2015-12-10 Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques

Country Status (9)

Country Link
US (7) US20160193285A1 (fr)
EP (2) EP3229824A4 (fr)
AU (3) AU2015360485B2 (fr)
CA (1) CA2970519A1 (fr)
HK (1) HK1245115A1 (fr)
IL (2) IL285440B2 (fr)
MA (1) MA41159A (fr)
WO (1) WO2016094662A1 (fr)
ZA (1) ZA201704026B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
WO2016126830A1 (fr) 2015-02-03 2016-08-11 Chiasma Inc. Méthode de traitement de maladies
RU2736590C2 (ru) 2016-02-16 2020-11-18 Стронгбридж Даблин Лимитед Велдореотид, обладающий плохой растворимостью в физиологических условиях, для применения при лечении акромегалии, акромегалии со злокачественным новообразованием, экспрессирующих sst-r5 опухолей, диабета 2 типа, гипергликемии и опухолей, связанных с гормонами
MX383392B (es) * 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
EP3355188B1 (fr) 2017-01-31 2021-08-25 OpenSynergy GmbH Visualisation instrumentale sur le tableau de bord d'une automobile par la vérification de trames d'une interface utilisateur graphique via un système d'exploitation temps-réel
CA3191084A1 (fr) 2020-09-09 2022-03-17 Gerald Burke Formulations d'un modulateur de somatostatine
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
BR112023024465A2 (pt) * 2021-05-25 2024-02-06 Crinetics Pharmaceuticals Inc Usos de um modulador de somatostatina para o tratamento de doença
CN120501873A (zh) * 2025-07-18 2025-08-19 中国人民解放军陆军军医大学 生长激素受体拮抗剂和核酸分子在制备预防或治疗视网膜新生血管类疾病的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198626B (en) 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
GB9203769D0 (en) 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
WO2005041901A2 (fr) 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine
PL1682091T3 (pl) 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
CA2563533C (fr) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
US20070219131A1 (en) 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CL2007000345A1 (es) 2006-02-09 2008-01-11 Univ Maryland Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
KR101814186B1 (ko) * 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
US20100151033A1 (en) 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
WO2016126830A1 (fr) * 2015-02-03 2016-08-11 Chiasma Inc. Méthode de traitement de maladies

Also Published As

Publication number Publication date
AU2020239738A1 (en) 2020-10-15
EP3229824A4 (fr) 2018-07-11
ZA201704026B (en) 2021-01-27
EP4321213A2 (fr) 2024-02-14
CA2970519A1 (fr) 2016-06-16
US20240041973A1 (en) 2024-02-08
US20210077569A1 (en) 2021-03-18
IL285440B2 (en) 2026-01-01
AU2024200465A1 (en) 2024-02-15
US20230201302A1 (en) 2023-06-29
US20190091285A1 (en) 2019-03-28
EP3229824A1 (fr) 2017-10-18
EP4321213A3 (fr) 2024-05-15
WO2016094662A1 (fr) 2016-06-16
US20250170204A1 (en) 2025-05-29
AU2015360485A1 (en) 2017-06-29
US20160193285A1 (en) 2016-07-07
IL252689B (en) 2021-09-30
HK1245115A1 (zh) 2018-08-24
US20220339240A1 (en) 2022-10-27
AU2015360485B2 (en) 2020-06-25
IL285440A (en) 2021-09-30
IL285440B1 (en) 2025-09-01
US10682387B2 (en) 2020-06-16
IL252689A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MA41159A (fr) Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
NL301217I2 (nl) tirzepatide en farmaceutisch aanvaardbare zouten daarvan
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
IL261479A0 (en) Orally administrable composition
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
EP3479800A4 (fr) Dispositif d'administration
EP3386484A4 (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
EP3554558A4 (fr) Conjugués ciblant hsp90 et formulations de ces derniers
EP3525841C0 (fr) Micro-dispositif d'administration
EP3437540A4 (fr) Support d'endoscope
DK4129270T3 (da) Oralt administrerede aminosyreformuleringer med modificeret udløsning
EP3556368A4 (fr) Agent thérapeutique contre l'onychomycose
EP3348648A4 (fr) Véhicule d'administration intracellulaire
EP2964658A4 (fr) Organofluoroborates substitués à titre d'agents d'imagerie
EP3416647A4 (fr) Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens
MA46867A (fr) Formulations pharmaceutiques
DK3244878T3 (da) Faste orale sammensætningsformer
MA39495A (fr) Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
EP3378606A4 (fr) Combinaison d'assistance
IL251859A0 (en) Methotrexate formulation
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs
EP3334413A4 (fr) Dispositif d'administration
FR3027521B1 (fr) Compositions pour administration par voie orale
EP3806679A4 (fr) Capsules destinées à être utilisées dans des vaporisateurs personnels
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren